COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders
https://t.co/Js3hEH3YSE
$CSCI
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer
https://t.co/YhEXlmoTPi
$CSCI #therapeutics
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
https://t.co/QDg0Xh2BCq
$CSCI #Therapeutics
We are focused on leveraging our research and clinical development expertise to advance medicines that improve the quality of life of patients with significant unmet medical needs across a range of therapeutic areas.
$CSCI #CoSciencs
Establishing #COSCIENS as a global leader in the development and commercialization of therapeutic assets that have the potential to enhance the lives of patients in need.
https://t.co/jT4rN7D0Wa
$CSCI
We are a specialty biopharmaceutical company dedicated to advancing health and wellness through our innovative portfolio of cosmeceutical, nutraceutical, and pharmaceutical products.
https://t.co/jT4rN7D0Wa
COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
https://t.co/b0cuW0p5Ko
$CSCI #Diagnostics#Therapeutics
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
https://t.co/IEjMNUaWr8
$CSCI #Diagnostics#Therapeutics
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
https://t.co/JfbrfRQDmD
$CSCI #Therapeutics